-
Taxonomy & unit
-
us-gaap: USD
-
Description
-
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
-
Summary
-
Enliven Therapeutics, Inc. quarterly/annual Net Income (Loss) Attributable to Parent history and growth rate from 2019 to 2023.
- Enliven Therapeutics, Inc. Net Income (Loss) Attributable to Parent for the quarter ending September 30, 2024 was -$23.2M, a 11.5% decline year-over-year.
- Enliven Therapeutics, Inc. Net Income (Loss) Attributable to Parent for the twelve months ending September 30, 2024 was -$85.2M, a 38% decline year-over-year.
- Enliven Therapeutics, Inc. annual Net Income (Loss) Attributable to Parent for 2023 was -$71.6M, a 90.1% decline from 2022.
- Enliven Therapeutics, Inc. annual Net Income (Loss) Attributable to Parent for 2022 was -$37.7M, a 52.2% decline from 2021.
- Enliven Therapeutics, Inc. annual Net Income (Loss) Attributable to Parent for 2021 was -$24.7M, a 40.2% increase from 2020.
Net Income (Loss) Attributable to Parent, Trailing 12 Months (USD)
Net Income (Loss) Attributable to Parent, Annual (USD)
Net Income (Loss) Attributable to Parent, YoY Annual Growth (%)